ScholarWorks@성균관대학교

상세 보기

박세훈 프로필 사진

박세훈

PARK, SE HOON

의과대학

의학과

2007

2026

연도별 연구 활동 현황

전체 432건 중 1번부터 10번까지의 결과를 표시합니다.

2026

Article

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

Perez-Gracia, Jose Luis ;
Mellado, Begoña ;
Hansen, Aaron Richard ;
Alonso-Gordoa, Teresa ;
Gomez-Roca, Carlos ;
... Park, Se Hoon ;
외 32명

2026-04-09
Journal for ImmunoTherapy of Cancer
BMJ PUBLISHING GROUP

Article

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study

Park, Se Hoon ;
Chang, Yen-Hwa ;
Lee, Jae Lyun ;
Choueiri, Toni K. ;
Kimura, Go ;
외 14명

2026-04
Cancer Research and Treatment
KOREAN CANCER ASSOCIATION

Article

Utility of the neutrophil-to-lymphocyte ratio extends to patients from East Asia

Yoo, Seong-Keun ;
Hwang, Jinha ;
Hong, Jung Yong ;
Kim, Seung Tae ;
Park, Se Hoon ;
... Park, Joon Oh ;
... Lee, Jeeyun

2026-03-16
Journal of Clinical Investigation
AMER SOC CLINICAL INVESTIGATION INC

Article

Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.

Choueiri, Toni K. ;
Merchan, Jaime R. ;
Patnaik, Amita ;
Drakaki, Alexandra ;
Rini, Brian I. ;
... Park, Se Hoon ;
외 14명

2026-03-01
Journal of Clinical Oncology
LIPPINCOTT WILLIAMS & WILKINS

Article

Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV plus P): Exploratory analysis from the phase 3 EV-302 trial of EV plus P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

Gupta, Shilpa ;
Bedke, Jens ;
Van Der Heijden, Michiel S. ;
Valderrama, Begona P. ;
Kikuchi, Eiji ;
... Park, Se Hoon ;
외 14명

2026-03-01
Journal of Clinical Oncology
LIPPINCOTT WILLIAMS & WILKINS

Article

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study

Motzer, Robert J. ;
Park, Se Hoon ;
McDermott, Raymond S. ;
Porta, Camillo ;
Heng, Daniel Yick Chin ;
외 13명

2026-03-01
Journal of Clinical Oncology
LIPPINCOTT WILLIAMS & WILKINS

Article

KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).

Albiges, Laurence ;
Suarez, Cristina ;
Beckermann, Kathryn ;
Stadler, Walter ;
Miller, Wilson H. ;
... Park, Se Hoon ;
외 14명

2026-03-01
Journal of Clinical Oncology
LIPPINCOTT WILLIAMS & WILKINS

Article

Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study

Jung, H.A. ;
Merkin, R. ;
Feng, A.L. ;
Lee, D. ;
Lee, K. ;
... Park, S. ;
... Sun, J.-M. ;
... Lee, S.-H. ;
... Ahn, J.S. ;
외 3명

2026-02
ESMO Open
Elsevier B.V.

Article

Phase 1 study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization

Drakaki, Alexandra ;
Park, Se Hoon ;
Castellano, Daniel ;
Siefker-Radtke, Arlene ;
Reimers, Melissa A. ;
외 16명

2026-02
Oncology Research and Treatment
KARGER

Article

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma

Kikuchi, Eiji ;
Van Der Heijden, Michiel S. ;
Valderrama, Begona P. ;
Gupta, Shilpa ;
Bedke, Jens ;
... Park, Se Hoon ;
외 14명

2026-01-21
International Journal of Clinical Oncology
SPRINGER JAPAN KK

1